COVID-19 highlighted the need for antivirals that can be rapidly deployed against both current and future coronavirus threats. CMX990 is a clinical stage coronavirus main protease (Mpro) inhibitor bearing a unique trifluoromethoxymethyl ketone warhead. Here, we broadly evaluate its pan-coronavirus target engagement, an...
N. G. R. Dayan Elshan, Karen C. Wolff, L. Riva et al.· bioRxiv· 0 citations
A previously unrecognized and novel, IL-27—independent CD4+ T cell axis through which PD-1 checkpoint blockade restores antiviral immunity during persistent viral infection is revealed, redefining the mechanistic landscape of checkpoint immunotherapy.
Prajakta Warang, J. Teijaro· Journal of Immunology· 0 citations
The vision is to establish JAK inhibition as a tractable strategy for restoring checkpoint sensitivity across solid tumors, providing the foundation for a biomarker-driven randomized phase 2 trial in checkpoint-refractory disease.
Rana Mckay, L.-J. Wei, Yu-Wei Chen et al.· The Oncologist· 0 citations
It is demonstrated that PD-1 inhibition enhances CD4+ T cell function, specifically through increased IL-21 production from T follicular helper (Tfh) cells which promotes both humoral and cytotoxic antiviral responses.
Prajakta Warang, J. Teijaro· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
